πŸ‡ΊπŸ‡Έ FDA
Patent

US 10323026

Heterocyclic compound

granted A61PA61P21/02A61P25/00

Quick answer

US patent 10323026 (Heterocyclic compound) held by Takeda Pharmaceutical Company Limited expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P21/02, A61P25/00, A61P25/04, A61P25/08